Robust Graft Survival and Normalized Dopaminergic Innervation Do Not Obligate Recovery in a Parkinson Disease Patient

摘要

ObjectiveThe main goal of dopamine cell replacement therapy in Parkinson disease (PD) is to provide clinical benefit mediated by graft survival with nigrostriatal reinnervation. We report a dichotomy between graft structure and clinical function in a patient dying 16 years following fetal nigral grafting.